Comparison of abciximab and eptifibatide on angiographic and clinical outcomes in rescue percutaneous coronary intervention for failed fibrinolytic therapy

Journal of Invasive Cardiology

Volumn 22, Issue 8, 2010, Pages 347-352

  Bajaj, Ravi R ^a   Mohammad, Atif ^a   Hong, Tony ^a   Irfan, Affan ^a   Sharieff, Waseem ^a   Bagnall, Alan ^a   Christie, Jo Ann ^a   Kutryk, Michael J B ^a   Chisholm, Robert J ^a   Cheema, Asim N ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

fibrinolytic therapy; glycoprotein IIb IIIa platelet receptor antagonist; rescue angioplasty

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIENOPYRIDINE DERIVATIVE; THROMBOCYTE RECEPTOR;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FIBRINOLYTIC THERAPY; HEART DEATH; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE PERFUSION; HEART PERFUSION; HEART REINFARCTION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE HEMORRHAGE; PREDICTOR VARIABLE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; THROMBOSIS;

EID: 77957026163     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005;353:2758-2768.
2. Sutton AG, Campbell PG, Graham R, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: The Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol 2004;44:287-296.
3. Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: A meta-analysis of randomized trials. J Am Coll Cardiol 2007;49:422-430.
4. Rasmanis G, Vesterqvist O, Green K, et al. Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction. British Heart Journal. 1992;68:374-376.
5. Merlini PA, Cugno M, Rossi ML, et al. Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction. Am J Cardiol 2004;93:822-825.
6. Ott I, Malcouvier V, Schomig A, Neumann FJ. Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction. Circulation 2002;105:279-281.
7. Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995;92:748-755.
8. Miller JM, Smalling R, Ohman EM, et al. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. Am J Cardiol 1999;84:779-784.
9. Petronio AS, Musumeci G, Limbruno U, et al. Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. Am Heart J 2002;143:334-341.
10. La Vecchia L, Favero L, Martini M, et al. Systematic coronary stenting after failed thrombolysis in high-risk patients with acute myocardial infarction: Procedural results and long-term follow-up. Coron Artery Dis 2003;14:395-400.
11. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
12. Schroder R. Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation 2004;110:e506-e510.
13. Tzivoni D, Koukoui D, Guetta V, et al. Comparison of Troponin T to creatine kinase and to radionuclide cardiac imaging infarct size in patients with ST-elevation myocardial infarction undergoing primary angioplasty. Am J Cardiol 2008;101:753-757.
14. Marzocchi A, Manari A, Piovaccari G, et al. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: Results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. Eur Heart J 2008;29:2972-2980.
15. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-1894.
16. Brown DL, Fann CS, Chang CJ. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 2001;87:537-541.
17. McKay RG, Boden WE. Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: Results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials. Curr Opin Cardiol 2001;16:364-369.
18. Furman MI, Krueger LA, Linden MD, et al. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost 2005;3:312-320.
19. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998;98:1085-1091.
20. Neumann FJ, Zohlnhofer D, Fakhoury L, et al. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999;34:1420-1426.
21. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163-167.
22. Blindt R, Bosserhoff AK, Krott N, et al. Decrease of vascular smooth muscle cell locomotion by abciximab, but not tirofiban: A possible role of different affinity to alpha v beta 3 integrins. Coron Artery Dis 2002;13:357-364.
23. Mazaev AA, Naimushin YA, Masenko VP, et al. Eptifibatide does not suppress the increase of inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. J Thromb Thrombolysis 2009;27:146-153.
24. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 2000;101:2788-2794.
25. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999;99:2720-2732.
26. Collet JP, Montalescot G, Lesty C, et al. Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation 2001;103:2328-2331.
27. Aymong ED, Curtis MJ, Youssef M, et al. Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting. Circulation 2002;105:2981-2985.
28. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-2701.
29. Gibson CM, Morrow DA, Murphy SA, et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: The PROTECT-TIMI-30 trial. J Am Coll Cardiol 2006;47:2364-2373.
30. Gibson CM, Cohen DJ, Cohen EA, et al. Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Am J Cardiol 2001;87:1293-1295.
31. Long KH, Ting HH, McMurtry EK, et al. A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions. Value Health 2008;11:462-469.
32. Gurm HS, Smith DE, Collins JS, et al. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: Insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol 2008;51:529-535.
33. Danzi GB, Sesana M, Capuano C, et al. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol 2004;94:35-39.
34. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: A randomized trial. JAMA 2005;293:2109-2117.
35. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: The MULTISTRATEGY randomized trial. JAMA 2008;299:1788-1799.
36. Kirtane AJ, Parise H, Mehran R, et al. Comparison of catheterization lab initiated abciximab and double-bolus eptifibatide during percutaneous coronary intervention in acute coronary syndromes: An ACUITY substudy. Circulation 2007;116(16 suppl):II629-II30.
37. Speich HE, Earhart AD, Hill SN, et al. Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab. J Thromb Haemost 2009;7:983-991.
38. Leung VW, Sunderji R, Zed PJ, Gin K. Switching from abciximab to eptifibatide for percutaneous coronary interventions: A local analysis (SWAP study). Can J Cardiol 2003;19:809-814.
39. Rebeiz AG, Johanson P, Green CL, et al. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am J Cardiol 2005;95:611-614.
40. Jong P, Cohen EA, Batchelor W, et al. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction. Am Heart J 2001;141:218-225.
41. Sundlof DW, Rerkpattanapitat P, Wongpraparut N, et al. Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty. Am J Cardiol 1999;83:1569-1571, A7.
42. Ellis K, Boccalandro F, Burjonroppa S, et al. Risk of bleeding complications is not increased in patients undergoing rescue versus primary percutaneous coronary intervention for acute myocardial infarction. J Interv Cardiol 2005;18:361-365.
43. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segmentelevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: A randomized double-blind trial. Circulation 2009;119:1933-1940.